サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1781985

モノクローナル抗体市場：供給源タイプ別、生産タイプ別、適応症別、エンドユーザー別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測

Monoclonal Antibody Market, By Source Type, By Production Types, By Indication, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 301 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
モノクローナル抗体市場：供給源タイプ別、生産タイプ別、適応症別、エンドユーザー別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測
出版日: 2025年07月04日
発行: AnalystView Market Insights
ページ情報: 英文 301 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

モノクローナル抗体市場規模は2024年に2億5,028万米ドルとなり、2025～2032年にかけてCAGR 11.92%で拡大

モノクローナル抗体市場-市場力学

慢性疾患の増加と生物工学の進歩がモノクローナル抗体市場の成長を加速

がんや自己免疫疾患などの慢性疾患の増加により、モノクローナル抗体療法への注目が高まっています。生物工学の飛躍的進歩により、疾病メカニズムのより正確な標的が可能となり、治療効果と患者の転帰が改善されました。例えば、米国食品医薬品局（FDA）は過去5年間だけでも20以上のモノクローナル抗体ベースの医薬品を承認しており、これはこれらの治療法に対する信頼の高まりを反映しています。さらに、米国国立衛生ラボ（NIH）のような機関によるイニシアチブが生物製剤の研究資金を後押しし、革新的な臨床検査を支援し、様々な慢性疾患や感染症におけるモノクローナル抗体の治療用途を拡大しています。

モノクローナル抗体市場-主要な洞察

リサーチアナリストの分析によると、世界市場は予測期間（2025～2032年）に約11.92%のCAGRで毎年成長すると推定されます。

供給源タイプ別では、ヒト化モノクローナル抗体は2024年に最大の市場シェアを示すと予測されました。

製品タイプ別では、in vitroが2024年の主要製品タイプです。

適応症別では、がんが2024年の主要適応症でした。

地域別では、北米が2024年の売上高をリードしています。

モノクローナル抗体市場-セグメンテーション分析

世界のモノクローナル抗体市場は、供給源タイプ、製品タイプ、適応症、エンドユーザー、地域に基づいてセグメント化されます。

市場は、ソースタイプに基づいて4つのカテゴリに分かれています。すなわち、マウスモノクローナル抗体、キメラモノクローナル抗体、ヒト化モノクローナル抗体、完全ヒトモノクローナル抗体です。ヒト化モノクローナル抗体は、免疫原性の低減と患者耐性の改善により優位を占めており、完全ヒト型抗体はその安全性プロファイルで珍重されています。キメラ抗体は効果的なターゲティングを提供するが免疫反応のリスクが高く、マウス抗体は免疫原性の懸念から使用は限定的です。

市場は生産タイプによって2つのカテゴリーに分けられます：生体内と生体外です。生体外は、モノクローナル抗体の製造において、より高い制御性、拡大性、一貫性により、市場をリードしています。一方、生体内法は一般的ではなく、大規模生産にはより時間がかかり、効率的ではないも、主に特定の研究目的で使用されています。

モノクローナル抗体市場-地理的洞察

モノクローナル抗体市場は、地域のヘルスケアインフラ、規制当局のサポート、疾患の流行によって、地理的に大きなばらつきがあります。北米は、国立がんラボのような政府機関からの強力な資金援助と先進的なバイオ医薬品研究施設により、モノクローナル抗体療法の迅速な承認と採用が促進され、依然として有力な地域となっています。欧州は、欧州の医薬品庁（EMA）のイニシアチブと個別化医療への投資の増加に支えられて、その後に続いています。アジア太平洋では、中国、日本、インドなどの国々で、慢性疾患の増加や医療制度の改善が需要を後押ししており、生物製剤へのアクセス強化を目的とした政府プログラムも勢いを増しています。ラテンアメリカや中東の新興市場も、医療保障の拡大や標的治療に対する意識の高まりを背景に、緩やかな成長を遂げています。しかし、一部の地域では、購入しやすい価格と入手しやすさの格差が依然として課題となっており、世界の市場拡大のペースに影響を及ぼしています。

モノクローナル抗体市場-競合情勢

モノクローナル抗体市場の競合情勢は、複数の主要バイオ医薬品企業が研究開発に多額の投資を行い、製品ポートフォリオの革新と拡大を図っていることが特徴です。大手企業は、新規治療法の開発を加速させるため、学術機関や政府研究機関としばしば共同研究を行っています。各社は、二重特異性抗体や抗体薬剤複合体といった抗体工学の進歩を通じて差別化を図り、アンメット・メディカル・ニーズに対応しています。FDAやEMAなどの規制当局からの承認は、競合のポジショニングを左右する重要なマイルストーンです。さらに、パートナーシップやライセンシング契約によって、より迅速な市場参入や地理的拡大が可能になります。競争が激化する中、各社は治療をより身近なものにするため、製造効率の改善や製造コストの削減にも取り組んでいます。個別化医療と免疫療法の重視は引き続き戦略的投資の原動力となっており、ダイナミックで進化する競合環境を育んでいます。

目次

第1章 モノクローナル抗体市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 モノクローナル抗体の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 モノクローナル抗体産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長展望マッピング
  • 規制枠組み分析

第5章 モノクローナル抗体市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 モノクローナル抗体市場情勢

  • モノクローナル抗体市場シェア分析、2024年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 モノクローナル抗体市場-供給源タイプ別

  • 概要
    • 供給源タイプ別セグメントシェア分析
    • マウスモノクローナル抗体
    • キメラモノクローナル抗体
    • ヒト化モノクローナル抗体
    • 完全ヒトモノクローナル抗体

第8章 モノクローナル抗体市場-生産タイプ別

  • 概要
    • 生産タイプ別セグメントシェア分析
    • 生体内
    • 生体外

第9章 モノクローナル抗体市場-適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • がん
      • 乳がん
      • 大腸がん
      • 肺がん
      • 卵巣がん
      • その他
    • 自己免疫疾患
    • 炎症性疾患
    • 感染症
    • 関節リウマチ
    • 多発性硬化症
    • 乾癬
    • クローン病
    • その他

第10章 モノクローナル抗体市場-エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 病院
    • 診断ラボ
    • 研究機関
    • 製薬バイオテクノロジー企業

第11章 モノクローナル抗体市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析-モノクローナル抗体産業

  • 競合ダッシュボード
    • 競合ベンチマーキング
    • 競合ポジショニング
  • 企業プロファイル
    • AbbVie
    • Alexion Pharmaceuticals
    • Amgen
    • Bayer Healthcare
    • Biogen
    • Bristol-Myers Squibb
    • Celltrion
    • Eli Lilly
    • Genentech（Roche subsidiary）
    • GlaxoSmithKline（GSK）
    • Johnson & Johnson
    • Merck & Co.
    • Novartis
    • Pfizer
    • Regeneron Pharmaceuticals
    • Roche
    • Samsung Bioepis
    • Sanofi
    • Takeda Pharmaceutical
    • UCB Pharma
    • その他

第13章 アナリストの全方位的展望

目次
Product Code: ANV5429

REPORT HIGHLIGHT

The Monoclonal Antibody Market size was valued at US$ 250.28 Million in 2024, expanding at a CAGR of 11.92% from 2025 to 2032.

The Monoclonal Antibody Market refers to the sector involved in the development and commercialization of antibodies engineered to target specific antigens, primarily used in diagnostics, therapeutics, and research applications. The increasing prevalence of chronic diseases like cancer and autoimmune disorders has significantly accelerated demand, with over 70% of biologic therapies in development focusing on monoclonal antibodies. However, high production costs and complex manufacturing processes often limit accessibility, posing challenges for widespread adoption. Advances in bioengineering and personalized medicine present substantial opportunities, enabling the development of more effective and tailored treatments. Additionally, the rising number of clinical trials utilizing monoclonal antibodies, which accounted for nearly 500 ongoing studies globally last year, highlights the expanding scope of this market segment. Despite hurdles, expanding applications in oncology, immunology, and infectious diseases continue to offer promising growth avenues.

Monoclonal Antibody Market- Market Dynamics

Rising prevalence of chronic diseases and advances in bioengineering to accelerate monoclonal antibody market growth

Rising prevalence of chronic diseases such as cancer and autoimmune disorders has intensified the focus on monoclonal antibody therapies, with the World Health Organization reporting that cancer accounted for nearly 10 million deaths worldwide in recent years. Breakthroughs in bioengineering have enabled more precise targeting of disease mechanisms, improving treatment efficacy and patient outcomes. For instance, the U.S. Food and Drug Administration (FDA) approved over 20 monoclonal antibody-based drugs in the past five years alone, reflecting the growing trust in these therapies. Additionally, initiatives by institutions like the National Institutes of Health (NIH) have boosted research funding for biologics, supporting innovative clinical trials and expanding the therapeutic applications of monoclonal antibodies across various chronic and infectious diseases.

Monoclonal Antibody Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.92% over the forecast period (2025-2032)

Based on Source Type segmentation, humanized monoclonal antibodies were predicted to show maximum market share in the year 2024

Based on Production Types segmentation, in vitro was the leading Production Type in 2024

Based on Indication segmentation, Cancer leading was the leading Indication in 2024

On the basis of region, North America was the leading revenue generator in 2024

Monoclonal Antibody Market- Segmentation Analysis:

The Global Monoclonal Antibody Market is segmented on the basis of Source Type, Production Types, Indication, End-User, and Region.

The market is divided into four categories based on Source Type: Murine Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, and Fully Human Monoclonal Antibodies. Humanized monoclonal antibodies dominate due to reduced immunogenicity and improved patient tolerance, followed by fully human antibodies prized for their safety profiles. Chimeric antibodies offer effective targeting but higher immune response risk, while murine antibodies see limited use due to immunogenicity concerns.

The market is divided into two categories based on Production Types: In Vivo and In Vitro. In vitro production leads the market due to greater control, scalability, and consistency in manufacturing monoclonal antibodies, while in vivo methods are less common, primarily used for specific research purposes despite being more time-consuming and less efficient for large-scale production.

Monoclonal Antibody Market- Geographical Insights

The Monoclonal Antibody Market exhibits significant geographical variation driven by regional healthcare infrastructure, regulatory support, and disease prevalence. North America remains a prominent region due to strong funding from government agencies like the National Cancer Institute and advanced biopharmaceutical research facilities, facilitating rapid approval and adoption of monoclonal antibody therapies. Europe follows closely, supported by initiatives from the European Medicines Agency (EMA) and increasing investments in personalized medicine. In Asia-Pacific, rising incidences of chronic diseases coupled with improving healthcare systems in countries such as China, Japan, and India are fueling demand, while government programs aimed at enhancing access to biologics are gaining momentum. Emerging markets in Latin America and the Middle East are also witnessing gradual growth, driven by expanding healthcare coverage and growing awareness about targeted therapies. However, disparities in affordability and availability remain challenges in some regions, influencing the pace of market expansion globally.

Monoclonal Antibody Market- Competitive Landscape:

The competitive landscape of the Monoclonal Antibody Market is characterized by the presence of several leading biopharmaceutical companies investing heavily in research and development to innovate and expand their product portfolios. Major players often collaborate with academic institutions and government research bodies to accelerate the development of novel therapies. Companies focus on differentiating themselves through advances in antibody engineering, such as bispecific antibodies and antibody-drug conjugates, to address unmet medical needs. Regulatory approvals from authorities like the FDA and EMA are critical milestones that influence competitive positioning. Additionally, partnerships and licensing agreements enable faster market entry and geographic expansion. With increasing competition, companies are also working on improving manufacturing efficiencies and reducing production costs to make treatments more accessible. The emphasis on personalized medicine and immunotherapy continues to drive strategic investments, fostering a dynamic and evolving competitive environment.

Recent Developments:

In September 2023, KBI Biopharma has launched SureMAB(TM), a new monoclonal antibody development platform. SureMAB(TM) accelerates the discovery and production of high-quality monoclonal antibodies, offering streamlined workflows and reduced timelines for clients developing novel biologic therapeutics across various disease areas.

In April 2025, the FDA announced a phased plan to replace animal testing requirements for monoclonal antibodies and other drugs with advanced, human-relevant methods like AI modeling and organoid testing, aiming to improve safety, accelerate development, and reduce drug costs and animal use.

In March 2024, Roche Pharma India launched Vabysmo (faricimab), the world's first bispecific monoclonal antibody, for treating neovascular age-related macular degeneration and diabetic macular edema. Vabysmo uniquely targets two disease pathways, offering improved vision outcomes and extended treatment intervals for Indian patients.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MONOCLONAL ANTIBODY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie
  • Alexion Pharmaceuticals
  • Amgen
  • Bayer Healthcare
  • Biogen
  • Bristol-Myers Squibb
  • Celltrion
  • Eli Lilly
  • Genentech (Roche subsidiary)
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
  • Roche
  • Samsung Bioepis
  • Sanofi
  • Takeda Pharmaceutical
  • UCB Pharma
  • Others

GLOBAL MONOCLONAL ANTIBODY MARKET, BY SOURCE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Murine Monoclonal Antibodies
  • Chimeric Monoclonal Antibodies
  • Humanized Monoclonal Antibodies
  • Fully Human Monoclonal Antibodies

GLOBAL MONOCLONAL ANTIBODY MARKET, BY PRODUCTION TYPES- MARKET ANALYSIS, 2019 - 2032

  • In Vivo
  • In Vitro

GLOBAL MONOCLONAL ANTIBODY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Cancer
  • Breast cancer
  • Colorectal cancer
  • Lung cancer
  • Ovarian cancer
  • Others
  • Autoimmune Diseases
  • Inflammatory Diseases
  • Infectious Diseases
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Psoriasis
  • Crohn's Disease
  • Others

GLOBAL MONOCLONAL ANTIBODY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmaceutical & Biotechnology Companies

GLOBAL MONOCLONAL ANTIBODY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Monoclonal Antibody Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Monoclonal Antibody Market Snippet by Source Type
    • 2.1.2. Monoclonal Antibody Market Snippet by Production Types
    • 2.1.3. Monoclonal Antibody Market Snippet by Indication
    • 2.1.4. Monoclonal Antibody Market Snippet by End-User
    • 2.1.5. Monoclonal Antibody Market Snippet by Country
    • 2.1.6. Monoclonal Antibody Market Snippet by Region
  • 2.2. Competitive Insights

3. Monoclonal Antibody Key Market Trends

  • 3.1. Monoclonal Antibody Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Monoclonal Antibody Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Monoclonal Antibody Market Opportunities
  • 3.4. Monoclonal Antibody Market Future Trends

4. Monoclonal Antibody Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Monoclonal Antibody Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Monoclonal Antibody Market Landscape

  • 6.1. Monoclonal Antibody Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Monoclonal Antibody Market - By Source Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Source Type, 2024 & 2032 (%)
    • 7.1.2. Murine Monoclonal Antibodies
    • 7.1.3. Chimeric Monoclonal Antibodies
    • 7.1.4. Humanized Monoclonal Antibodies
    • 7.1.5. Fully Human Monoclonal Antibodies

8. Monoclonal Antibody Market - By Production Types

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Production Types, 2024 & 2032 (%)
    • 8.1.2. In Vivo
    • 8.1.3. In Vitro

9. Monoclonal Antibody Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 9.1.2. Cancer
      • 9.1.2.1. Breast cancer
      • 9.1.2.2. Colorectal cancer
      • 9.1.2.3. Lung cancer
      • 9.1.2.4. Ovarian cancer
      • 9.1.2.5. Others
    • 9.1.3. Autoimmune Diseases
    • 9.1.4. Inflammatory Diseases
    • 9.1.5. Infectious Diseases
    • 9.1.6. Rheumatoid Arthritis
    • 9.1.7. Multiple Sclerosis
    • 9.1.8. Psoriasis
    • 9.1.9. Crohn's Disease
    • 9.1.10. Others

10. Monoclonal Antibody Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Diagnostic Laboratories
    • 10.1.4. Research Institutes
    • 10.1.5. Pharmaceutical & Biotechnology Companies

11. Monoclonal Antibody Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Monoclonal Antibody Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Monoclonal Antibody Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Monoclonal Antibody Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Monoclonal Antibody Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Monoclonal Antibody Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Monoclonal Antibody Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AbbVie
    • 12.2.2. Alexion Pharmaceuticals
    • 12.2.3. Amgen
    • 12.2.4. Bayer Healthcare
    • 12.2.5. Biogen
    • 12.2.6. Bristol-Myers Squibb
    • 12.2.7. Celltrion
    • 12.2.8. Eli Lilly
    • 12.2.9. Genentech (Roche subsidiary)
    • 12.2.10. GlaxoSmithKline (GSK)
    • 12.2.11. Johnson & Johnson
    • 12.2.12. Merck & Co.
    • 12.2.13. Novartis
    • 12.2.14. Pfizer
    • 12.2.15. Regeneron Pharmaceuticals
    • 12.2.16. Roche
    • 12.2.17. Samsung Bioepis
    • 12.2.18. Sanofi
    • 12.2.19. Takeda Pharmaceutical
    • 12.2.20. UCB Pharma
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us